Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Return on Invested Capital (2016 - 2025)

Historic Return on Invested Capital for Cytosorbents (CTSO) over the last 14 years, with Q3 2025 value amounting to 0.7%.

  • Cytosorbents' Return on Invested Capital rose 7100.0% to 0.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.7%, marking a year-over-year increase of 7100.0%. This contributed to the annual value of 0.78% for FY2024, which is 1900.0% up from last year.
  • Cytosorbents' Return on Invested Capital amounted to 0.7% in Q3 2025, which was up 7100.0% from 1.13% recorded in Q1 2025.
  • Over the past 5 years, Cytosorbents' Return on Invested Capital peaked at 0.12% during Q1 2021, and registered a low of 1.41% during Q3 2024.
  • For the 5-year period, Cytosorbents' Return on Invested Capital averaged around 0.74%, with its median value being 0.79% (2022).
  • As far as peak fluctuations go, Cytosorbents' Return on Invested Capital plummeted by -5800bps in 2022, and later skyrocketed by 7100bps in 2025.
  • Over the past 5 years, Cytosorbents' Return on Invested Capital (Quarter) stood at 0.33% in 2021, then plummeted by -147bps to 0.82% in 2022, then tumbled by -36bps to 1.12% in 2023, then decreased by -10bps to 1.23% in 2024, then surged by 43bps to 0.7% in 2025.
  • Its Return on Invested Capital was 0.7% in Q3 2025, compared to 1.13% in Q1 2025 and 1.23% in Q4 2024.